80 related articles for article (PubMed ID: 36355212)
1. External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme.
Esposito Abate R; Cheetham MH; Fairley JA; Pasquale R; Sacco A; Nicola W; Deans ZC; Patton SJ; Normanno N
Virchows Arch; 2023 Feb; 482(2):347-355. PubMed ID: 36355212
[TBL] [Abstract][Full Text] [Related]
2. Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing.
Zhang W; Wang R; Fang H; Ma X; Li D; Liu T; Chen Z; Wang K; Hao S; Yu Z; Chang Z; Na C; Wang Y; Bai J; Zhang Y; Chen F; Li M; Chen C; Wei L; Li J; Chang X; Qu S; Yang L; Huang J
Clin Transl Med; 2021 May; 11(5):e415. PubMed ID: 34047470
[TBL] [Abstract][Full Text] [Related]
3. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort.
Bevins N; Sun S; Gaieb Z; Thorson JA; Murray SS
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217764
[TBL] [Abstract][Full Text] [Related]
4. Assessments of tumor mutational burden estimation by targeted panel sequencing: A comprehensive simulation analysis.
Li D; Wang D; Johann DJ; Hong H; Xu J
Exp Biol Med (Maywood); 2023 Nov; 248(21):1918-1926. PubMed ID: 38062992
[TBL] [Abstract][Full Text] [Related]
5. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges.
Fancello L; Gandini S; Pelicci PG; Mazzarella L
J Immunother Cancer; 2019 Jul; 7(1):183. PubMed ID: 31307554
[TBL] [Abstract][Full Text] [Related]
6. Harmonizing tumor mutational burden analysis: Insights from a multicenter study using in silico reference data sets in clinical whole-exome sequencing (WES).
Yu L; Zhang Y; Wang D; Li L; Zhang R; Li J
Am J Clin Pathol; 2024 May; ():. PubMed ID: 38733635
[TBL] [Abstract][Full Text] [Related]
7. Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing.
Patton S; Normanno N; Blackhall F; Murray S; Kerr KM; Dietel M; Filipits M; Benlloch S; Popat S; Stahel R; Thunnissen E
Br J Cancer; 2014 Jul; 111(2):413-20. PubMed ID: 24983368
[TBL] [Abstract][Full Text] [Related]
8. Tumor Mutation Burden as a Cornerstone in Precision Oncology Landscapes: Effect of Panel Size and Uncertainty in Cutoffs.
Budak B; Arga KY
OMICS; 2024 Apr; 28(4):193-203. PubMed ID: 38657109
[TBL] [Abstract][Full Text] [Related]
9. Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies.
Ahmed J; Das B; Shin S; Chen A
Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136385
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for Tumor Mutational Burden Assay Validation and Reporting: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, and Society for Immunotherapy of Cancer.
Furtado LV; Bifulco C; Dolderer D; Hsiao SJ; Kipp BR; Lindeman NI; Ritterhouse LL; Temple-Smolkin RL; Zehir A; Nowak JA
J Mol Diagn; 2024 Jun; ():. PubMed ID: 38851389
[TBL] [Abstract][Full Text] [Related]
11. External quality assessment scheme for sperm DNA fragmentation: a pilot study in China.
Zheng Y; Wu YB; Jia YL; Ying LJ; Yang TT; Cheng QY; Qin J; Luo C; Yu L; Li FP
Basic Clin Androl; 2023 Nov; 33(1):36. PubMed ID: 38012601
[TBL] [Abstract][Full Text] [Related]
12. Result of a Pilot External Quality Assessment Scheme for Clinical Diagnosis of Inherited Metabolic Disorders in China.
Du Y; Jiang P; Yang J; Zhao M; Wu L; Hui Y; Geng G; Lai G; Li W; Mao J; Zhang M; Ji X; Qiu L; Liu Y; Gan X; Li D; He H; Liu X; Wang Y; Hao S; Zhang P; Yu C; Miao J; Jiang Y; Gu X; Jiang J; Zhang B; Wang X; Wang Z; Wang W; Yang Y
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623669
[TBL] [Abstract][Full Text] [Related]
13. Enhancing the quality of panel-based tumor mutation burden assessment: a comprehensive study of real-world and in-silico outcomes.
Zhang Y; Wang D; Zhao Z; Peng R; Han Y; Li J; Zhang R
NPJ Precis Oncol; 2024 Jan; 8(1):18. PubMed ID: 38263314
[TBL] [Abstract][Full Text] [Related]
14. TMBcalc: a computational pipeline for identifying pan-cancer Tumor Mutational Burden gene signatures.
Privitera GF; Alaimo S; Caruso A; Ferro A; Forte S; Pulvirenti A
Front Genet; 2024; 15():1285305. PubMed ID: 38645485
[TBL] [Abstract][Full Text] [Related]
15. Quality-Assured Analysis of PIK3CA Mutations in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Tissue: A Story About the Need for Proficiency Testing for High-Quality Molecular Biomarker Reporting in Precision Medicine.
Schmidt C; Stöhr R; Dimitrova L; Beckmann MW; Rübner M; Fasching PA; Denkert C; Lehmann U; Vollbrecht C; Haller F; Hartmann A; Erber R
J Mol Diagn; 2024 Apr; ():. PubMed ID: 38697471
[TBL] [Abstract][Full Text] [Related]
16. NGS for (Hemato-) Oncology in Belgium: Evaluation of Laboratory Performance and Feasibility of a National External Quality Assessment Program.
Delcourt T; Vanneste K; Soumali MR; Coucke W; Ghislain V; Hebrant A; Van Valckenborgh E; De Keersmaecker SCJ; Roosens NH; Van De Walle P; Van Den Bulcke M; Antoniou A
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138022
[TBL] [Abstract][Full Text] [Related]
17. Managing Deviating EQA Results: A Survey to Assess the Corrective and Preventive Actions of Medical Laboratories Testing for Oncological Biomarkers.
Keppens C; Schuuring E; Dequeker EM
Diagnostics (Basel); 2020 Oct; 10(10):. PubMed ID: 33080995
[TBL] [Abstract][Full Text] [Related]
18. Multicentric pilot study to standardize clinical whole exome sequencing (WES) for cancer patients.
Menzel M; Ossowski S; Kral S; Metzger P; Horak P; Marienfeld R; Boerries M; Wolter S; Ball M; Neumann O; Armeanu-Ebinger S; Schroeder C; Matysiak U; Goldschmid H; Schipperges V; Fürstberger A; Allgäuer M; Eberhardt T; Niewöhner J; Blaumeiser A; Ploeger C; Haack TB; Tay TKY; Kelemen O; Pauli T; Kirchner M; Kluck K; Ott A; Renner M; Admard J; Gschwind A; Lassmann S; Kestler H; Fend F; Illert AL; Werner M; Möller P; Seufferlein TTW; Malek N; Schirmacher P; Fröhling S; Kazdal D; Budczies J; Stenzinger A
NPJ Precis Oncol; 2023 Oct; 7(1):106. PubMed ID: 37864096
[TBL] [Abstract][Full Text] [Related]
19. Panels and models for accurate prediction of tumor mutation burden in tumor samples.
Martínez-Pérez E; Molina-Vila MA; Marino-Buslje C
NPJ Precis Oncol; 2021 Apr; 5(1):31. PubMed ID: 33850256
[TBL] [Abstract][Full Text] [Related]
20. Model of implementing proficiency testing in Vietnam, a developing country.
Van HT; Tran VT; Ha MT; Vu QH
Pract Lab Med; 2023 Nov; 37():e00339. PubMed ID: 37886110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
